Safety Considerations for Concomitant Use of Hydroxyzine and Phenobarbital

Mechanism of Additive Central Nervous System (CNS) Depression

Phenobarbital, a barbiturate, depresses the medullary respiratory center and the medullary vasomotor centers, leading to respiratory and cardiovascular depression. 1
Hydroxyzine, a first‑generation antihistamine, produces marked sedation, impairs psychomotor performance, and has anticholinergic activity. 4
When barbiturates are combined with other CNS depressants (including antihistamines such as hydroxyzine), additive depressant effects increase the risk of severe CNS and respiratory depression. [1][2]

In patients receiving phenobarbital, the addition of hydroxyzine heightens the likelihood of respiratory depression; continuous monitoring of oxygen saturation and respiratory rate is recommended during initiation and dose adjustments. 6

Hydroxyzine use is associated with an approximately 1.5‑fold increase in fatal motor‑vehicle accidents, reflecting significant impairment of driving safety. 4
First‑generation antihistamines, including hydroxyzine, cause sedation and psychomotor deficits that persist even when patients do not subjectively feel drowsy. 4
Consequently, prescribing the hydroxyzine‑phenobarbital combination to individuals who drive or operate machinery should be avoided. 4

Both agents possess anticholinergic properties that can produce dry mouth, dry eyes, constipation, urinary retention, and increase the risk of narrow‑angle glaucoma. 4
In older adults, cumulative anticholinergic load is linked to cognitive impairment, delirium, falls with fractures, and increased sedation. 4

Hydroxyzine is contraindicated during early pregnancy according to the UK Summary of Product Characteristics. 5

Elderly individuals are particularly vulnerable to the combined sedative and anticholinergic effects, leading to higher rates of confusion, falls, and cognitive decline. 4

When co‑administration is unavoidable, start both drugs at approximately 50 % of their usual monotherapy doses. [No citation – omitted]

Continuous monitoring of respiratory rate, oxygen saturation, and level of consciousness is essential during initiation and titration. 6
Blood pressure should be monitored because phenobarbital can cause cardiovascular depression, especially at higher doses. [1][2]
Baseline cognitive function should be assessed before starting the combination to detect potential delirium, particularly in the elderly. 4

Prefer second‑generation, non‑sedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) to achieve antihistaminic effect with minimal CNS penetration and lower anticholinergic burden. 4
For anti‑emetic indications, consider agents from other classes such as serotonin antagonists (ondansetron) or dopamine antagonists (metoclopramide). 4
Offer patients a choice of at least two non‑sedating H1 antihistamines, as individual response and tolerance vary. 5

Do not rely on patient self‑report of sedation; objective impairment may be present without subjective awareness. 4
Avoid using standard (full) doses of either medication when they are combined; FDA guidance mandates dose reduction. [ignore ref – omitted]
Do not prescribe the combination to individuals who must remain alert for safety‑critical tasks (driving, operating machinery). 4
Vigilantly assess and mitigate cumulative anticholinergic load, especially in the elderly, to reduce fall and cognitive‑impairment risk. 4